KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Gsk (GSK) Other Operating Expenses (2019 - 2022)

Gsk has reported Other Operating Expenses over the past 6 years, most recently at -$275.6 million for Q4 2022.

  • For Q4 2022, Other Operating Expenses rose 59.43% year-over-year to -$275.6 million; the TTM value through Mar 2026 reached $0.0, changed 0.0%, while the annual FY2025 figure was $21.3 million, 101.08% up from the prior year.
  • Other Operating Expenses for Q4 2022 was -$275.6 million at Gsk, down from $794.4 million in the prior quarter.
  • Over five years, Other Operating Expenses peaked at $1.1 billion in Q4 2019 and troughed at -$679.4 million in Q4 2021.
  • A 4-year average of $86.4 million and a median of -$16.0 million in 2019 define the central range for Other Operating Expenses.
  • Biggest five-year swings in Other Operating Expenses: tumbled 1613.29% in 2021 and later surged 203.2% in 2022.
  • Year by year, Other Operating Expenses stood at $1.1 billion in 2019, then crashed by 95.92% to $44.9 million in 2020, then tumbled by 1613.29% to -$679.4 million in 2021, then surged by 59.43% to -$275.6 million in 2022.
  • Business Quant data shows Other Operating Expenses for GSK at -$275.6 million in Q4 2022, $794.4 million in Q1 2022, and -$679.4 million in Q4 2021.